Attention-deficit/hyperactive disorder pre-adulthood and later adverse health outcomes: The 1987 Finnish birth cohort study

G. David Batty, DSc (Email: david.batty@ucl.ac.uk | ORCID: 0000-0003-1822-5753)[a]
Mika Gissler, PhD (mika.gissler@thl.fi | 0000-0001-8254-7525)[b,c,d]
Seyed Ehsan Mouasvi, MPH (mousavi.e@tbzmed.ac.ir | 0000-0003-4747-5639)[e,f]
Varun Warrier, PhD (vw260@medschl.cam.ac.uk | 0000-0003-4532-8571)[g,h]
Tamsin Ford, PhD (tjf52@medschl.cam.ac.uk | 0000-0001-5295-4904)[g]
Markus Keski-Säntti, MSc (markus.keski-santti@thl.fi | 0009-0001-4717-2104)[b]

[a]Department of Epidemiology and Public Health, University College London, London, UK
[b]Department of Data and Analytics, Finnish Institute for Health and Welfare, Helsinki, Finland
[c]Academic Primary Health Care Centre, Region Stockholm, Sweden
[d]Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
[e]Neurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
[f]Social Determinants of Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
[g]Department of Psychiatry, University of Cambridge, Cambridge, UK
[h]Department of Psychology, University of Cambridge, Cambridge, UK

Correspondence: David Batty, Department of Epidemiology and Public Health, University College London, 1-19 Torrington Place, London, UK, WC1E 6BT. E. david.batty@ucl.ac.uk

Manuscript characteristics: 2334 words; 1 table, 3 figures, & 1 supplemental table

Funding: The present paper received no direct funding. GDB is supported by the UK Medical Research Council (MR/P023444/1) and the US National Institute on Aging (1R56AG052519-01, 1R01AG052519-01A1).

Contributions: GDB generated the idea for the present manuscript, developed an analytical plan, and wrote the manuscript. MG established the cohort study, developed an analytical plan, and edited the manuscript. SEM, VW, and TF edited the manuscript. MK-S developed an analytical plan, analysed the data, produced the figures, and edited the manuscript.

Conflict of Interest: None declared.

Abstract

Whereas attention-deficit/hyperactive disorder (ADHD) is correlated with later risk of depression, anxiety, and substance misuse, the relationship with other health endpoints is uncertain. In a full-nation birth cohort study, we used a phenotype-wide approach to explore the influence of an ADHD diagnosis in childhood/adolescence with later disease and injury. Comprising 53147 (25731 female) children born in a single year, the 1987 Finnish Birth Cohort was generated from linkage of routinely collected data. Using international classification disease codes, ADHD diagnosis was captured from in- and out-patient hospital records up to age 18 years and study members continued to be surveilled for other diagnoses until 2020 (aged 33 years). In logistic regression analyses, effect estimates were adjusted for education achievement, family socioeconomic status, and multiple comparisons. Pre-adulthood, 0.43% (N=228) of study members were diagnosed with ADHD. In people with ADHD relative to population controls, there was a heightened risk of developing all 17 specific health endpoints examined. Of these, only 5 reached statistical significance after correction for socioeconomic status, education, and multiple comparison (odds ratio; 99.7%): substance abuse disorders (2.27; 1.28, 3.81), mood disorders (2.46; 1.50, 3.90), neurotic disorders (2.12; 1.25, 3.43), epilepsy (4.65; 1.86, 9.75), and poisoning (2.30; 1.02, 4.51). In the present study, children and adolescents with ADHD had an increased future burden of psychological and neurological conditions but not somatic disorders.

Introduction

First posited over four decades ago, the developmental origins of adult disease – the notion that adverse health in later life is influenced by early life exposures – has traditionally focused on the deterministic role of markers of physical development,[1] such as body weight from birth through to adolescence, physical stature, and age at onset of puberty.[2-5] By contrast, it is only in the last 5 years that the role of neurological development and associated disorders such as intellectual disability, autism, Tourette syndrome/Tic disorder, and attention-deficit/hyperactive disorder (ADHD) in the occurrence of adult disease and injury have been systematically examined.[6-9] Of these neurodevelopmental conditions, if ADHD is shown to be connected to later health, it holds the largest potential for event prevention given that it is the most commonly occurring neurodevelopmental disorder (3-7% prevalence[10]), and its core symptoms of age-inappropriate levels of distraction, restlessness, and impulsivity are eminently modifiable via prescription psychostimulants and psychosocial intervention.[11]

The greater prevalence of obesity, unfavourable health behaviours such as cigarette smoking and heavy alcohol intake, educational challenges, and poverty in people with ADHD relative to population controls[12] suggests the potential development of an array of related health outcomes in affected individuals. Thus, people with people with this neurodevelopmental disorder appear to have a greater burden of psychological ill-health and addiction such as depression,[13,14] anxiety,[15] and substance misuse,[16] although these are not universal observations.[17] Most recently, nascent findings from extended follow-up in cohort studies generated from linked administrative records indicate that younger people diagnosed with ADHD subsequently experience around twice the rate of somatic disease, including diabetes,[18] dementia,[19] and cardiovascular disease.[20]

Owing to the core symptoms of ADHD, there are also reasons to anticipate associations with lesser-examined health endpoints such as respiratory illness and unintentional injury. Thus, potentially via a lack of compliance with preventative measures such as mask wearing and handwashing, ADHD-affected individuals have been shown to have a higher burden of COVID-19[21] compared with rates in the general population; the connection with other common pulmonary infections, such as influenza and pneumonia, is untested however. Unintentional injury, such as road traffic accidents[22] may also be more

common in people with this neurodevelopmental disorder because of inattention, impulsivity, and longer reaction time.[23]

To address the general paucity of evidence for health outcomes in relation to antecedent ADHD, and to test some of these hypothesised associations, we undertook analyses of an on-going, full nation birth cohort of individuals born in Finland in 1987 with routinely collected data on ADHD, covariates, and episodes of adverse health. Our analyses also allow us to examine the potential explanatory role of confounding factors, a perennial concern in observational studies. In the present context, these include socioeconomic background and educational performance, both of which have been consistently linked to ADHD[24] and a series of health conditions.[25]

Methods

Described in detail elsewhere,[26] the 1987 Finnish Birth Cohort was generated from the linkage of routinely collected data using the personal identification number allocated to every citizen. The cohort comprises 59476 people (figure 1). Study approval was provided by the Ethical committee at the Finnish Institute for Health and Welfare (§28/2009). The composition of this manuscript conforms to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement.[27]

Ascertainment of ADHD and health outcomes

The Finnish Care Register for Health Care (formerly the Hospital Discharge Register) captures in- (1969-present) and out-patient care episodes (1998-present) from all hospitals in the country.[28] Coded according to the International Classification of Diseases (ICD) versions 9 (1987-1995) and 10 (1996-2004), a diagnosis of ADHD was denoted by codes 314 (ICD-9) and F90 (ICD-10). ICD codes for the health outcomes in the present analyses are listed in figures 2 and 3.

Assessment of covariates

Parental socioeconomic status, extracted from the Register of Social Assistance, was denoted by the duration (months) the study members' carer, typically the parent, was in receipt of government income support. Longer duration denotes greater socioeconomic disadvantage. For educational performance of

the study member, we used school grade point average (score range: 4-10) as provided by the Finnish

National Agency for Education. A greater score is indicative of higher educational performance.

Derivation of the analytical sample and statistical analyses

From the 59476 births (29041 females) in 1987, we excluded people who subsequently died or

emigrated before the end of follow-up 33 years later (31 December 2020) and those missing covariate

data (figure 1). Analyses were based on a sample of 53147 individuals (25731 women) in which ADHD

on or before the 18th birthday of the study members (calendar year 2005) was related to the occurrence

of adverse health events between age 19 and 33 (2005-2020). During follow-up, a study member could

conceivably not have diagnosis of a health episode, a single diagnosis, or multiple diagnoses made on

single or multiple occasions. When there were multiple events recorded, each contributed separately to

the analyses of a specific health outcome. Thus, in preliminary analyses, of the 228 individuals with

ADHD diagnosis, during 15 years of follow-up, 208 had one or more contact with hospital services for a

total of 10494 contacts. In the ADHD-free group, of the 52919 people, 46874 had contact with hospital

services for a total of 1452935 contacts.

We used logistic regression analyses to computed odds ratios to summarise the relationship between

ADHD and later event diagnosis. Taking a phenotype-wide approach, those outcomes with 10 or more

events in the ADHD group and population controls qualified for inclusion in our analyses. In minimally-

adjusted analyses (model 1), we controlled odds ratios for sex; with this being a single-year birth cohort,

no adjustment for age was required. Further adjustment was then made for the educational performance

of the study member and family socioeconomic status (model 2). Using the Bonferroni correction for

multiple testing was applied to the computation of all effect estimates, with statistical significance set at

p=0.004 (96.6% confidence intervals) for the analyses featured in figure 2 on ICD chapters (14

outcomes) and p=0.003 (99.7 confidence intervals) for the analyses featured in figure 3 for chapter

disaggregation (17 outcomes).[29] Change in odds ratios following adjustment for multiple covariates

relative to minimal correction was computed using standard formulae ((ln odds ratio[Model 1] – ln odds

ratio [Model 2]) / ln odds ratio[Model 1]) with the product expressed as a percentage.[30]

Results

In the analytical sample of 53147 individuals (25731 women), 0.43% (N=228) were diagnosed with ADHD on or before their 18th birthday. Relative to their unaffected counterparts, study members with ADHD were more likely to be male (51 versus 86%), and have a less favourable cluster of social characteristics. Thus, people with ADHD were more likely to have a lower grade point average (6.9 versus 7.8) and have parents who were in receipt of state welfare payments for a longer period (48.8 versus 17.6 months).

After fifteen years of follow-up, 89% of the full cohort (N=47082) had experienced in- or out-patient contact with a hospital for any health event (figure 1 and table 1), with hospital visits marginally more common in people with ADHD (91%) than their unaffected counterparts (89%). In figure 2, we depict the association between ADHD and subsequent hospitalisation for outcomes denoted by 14 ICD chapters. In analyses corrected for sex and multiple comparisons (model 1), there was a higher risk of all 14 endpoints in people diagnosed with ADHD relative to population controls, although statistical significance was only apparent for half. Where the confidence interval did not include unity, the magnitude of the odds ratio (99.6% confidence interval) ranged between 1.65 (1.07, 2.49) for diseases of the musculoskeletal system and 4.88 (3.29, 7.20) for mental and behavioural disorders. After further adjustment for socioeconomic position and educational achievement (model 2), there was marked attenuation in all point estimates (range: 10.2-63.5%). Only three ADHD–health associations remained statistically significant: mental and behavioural disorders (3.51; 2.35, 5.22), diseases of the eye (2.04; 1.19, 3.33), diseases of the nervous system (1.81; 1.07, 2.91).

Next, in figure 3 we show the association of ADHD diagnosis with 17 outcomes disaggregated from the ICD chapters in figure 2. Again, a higher risk of all these endpoints was seen in people with ADHD, however, only nine of these associations were statistically significant (99.7% confidence interval) after minimal adjustment and Bonferroni correction (model 1). After taking into account differences in parental socioeconomic status and study members' education achievement, 5 associations remained: epilepsy (4.65; 1.86, 9.75), mood disorders (2.46; 1.50, 3.90), poisoning (2.30; 1.02, 4.51), substance abuse disorder (2.27; 1.28, 3.81), and neurotic disorders (2.12 [1.25–3.43]).

Lastly, to increase confidence in our new results for hospitalisations and antecedent ADHD, we attempted to replicate well-explored predictors of mortality in the same population (supplemental table 1). In sex-adjusted analyses, men (versus women odds ratio; 95% confidence interval: 2.95; 2.46, 3.56), study members with lower educational achievement (low versus high grade point average: 2.37; 2.01, 2.79), those from socioeconomically disadvantaged families (per SD longer duration of family income support: 1.28; 1.21, 1.34), and those diagnosed with ADHD (versus none: 2.15; 0.97, 4.08) all experienced a higher risk of premature mortality.

Discussion

The main finding of the present study was that, after taking into account covariates and multiple testing in a phenotype-wide approach, pre-adult ADHD was associated with later occurrence of substance abuse, mood disorders, neurotic disorders, epilepsy, and poisoning. For those less well-examined health outcomes for which we had a working hypothesis – for example, bacterial/viral infection, road traffic accidents, and falls – while risk was significantly elevated in people with ADHD in basic analyses, there was marked attenuation to the point of non-significance after poverty and educational performance were added to the multivariable model.

Comparison with existing studies

Our results add to the rapidly growing, if currently modest evidence base on the health consequences of ADHD. Consistent with other studies, we found a higher occurrence of mood disorders (depression),[13,14] anxiety (neurotic) disorders,[15] and substance abuse[16] in people with ADHD relative to their unaffected peers. We did not have a sufficiently high number of people with substance use disorders to disaggregate this endpoint further. Meta-analyses suggest that, relative to population controls, people with ADHD are three times as likely to be nicotine-dependent[31] and have a drug use disorder[32] which includes marijuana[33] and alcohol.[13] Several psychological processes could explain the higher burden of these outcomes in the ADHD-affected, including self-medication whereby nicotine enhances mental focus and ethanol alleviates feelings of restlessness, hyperactivity and anxiety.[34]

We also found a raised risk of adult epilepsy in people diagnosed with ADHD in childhood/adolescence. Studies in this area have traditionally examined the role of epilepsy in the development of ADHD rather

than the converse.[35] In a rare exception, reports from a Taiwanese cohort also generated from registry

linkages, suggest ADHD was associated with a four-fold elevation in the risk of this neurological

condition in later life.[36] While the pathways connecting epilepsy and ADHD have yet to be identified,

there may be overlapping pathophysiologic and genetic mechanisms at play.

Lastly, in our study, people with ADHD had a higher likelihood of experiencing poisonings requiring

hospital attention. Ascribing intention to episodes of poisonings is challenging for an attending-

physician, however, those of deliberate[37] and unknown aim[38] have both be shown to be more common in

people with ADHD in meta-analyses and large-scale administrative datasets, respectively. Deliberate

poisoning accords with the literature on the elevated burden of self-harm and attempted suicide in

people who are neurodiverse, particularly those with ADHD.[39] When accidental, this could be a product

of lower risk perception in people with an ADHD diagnosis who, on average, have lower cognitive

function relative to the general population.[23] This explanation has been advanced for the elevated risk of

unintentional injury in people who achieve lower scores on standard IQ tests.[40] In controlling for

educational performance, a close correlate of IQ,[41] the magnitude of the ADHD–poisoning relation,

while clearly attenuated, was not eliminated. This would seem to implicate additional mechanisms

underpinning this association.

Study strengths and limitations

Our study has some strengths. These include the use of a full nation birth cohort with complete linkage

to health records, so minimising concerns regarding selection bias and generalisability. Second, in our

analyses we were able to replicate well-established findings in ADHD population-based research: a

higher prevalence of being male, socioeconomically deprived, and diminished academic performance in

individuals with a diagnosis of this neurodevelopmental condition. These characteristics are also known

predictors of total mortality[42,43] – again, observations made in the present dataset. Collectively, these

findings give us confidence in the newer relationships reported here for ADHD and specific health

conditions.

Our work is not without its limitations. First, all diagnoses – ADHD and health outcomes – were based

on conditions severe enough to warrant hospital attention, whether in- or out-patient; people with less

severe ADHD symptoms were therefore not captured. That the period prevalence of ADHD herein is based on administrative data may lead to some under-detection, such that studies which include sample-wide assessment of ADHD symptoms yield higher estimates.[10] Relatedly, it is unclear if symptoms below current diagnostic thresholds for ADHD have an impact on adverse health events. Second, although we only computed effect estimates for those health endpoints with ten or more events, the breadth of the resulting confidence intervals suggests some analyses were underpowered. For instance, after disaggregating the outcomes in figure 2, confidence intervals in figure 3 are noticeably wider denoting lower precision. Third, in an attempt to ascertain independence of association, we adjusted for educational performance of the study member; this is a moot given that this characteristic may lie on mechanistic pathway connecting ADHD with injury and disease. Lastly, out-patient care episodes, including those for ADHD, were recorded from 1998 when study members were aged 11. As such, people with a prior ADHD diagnosis who did not continue to seek hospital care would not have been included in the ADHD group.

Future research directions

ADHD, in contrast to other neurodevelopmental disorders such as autism and intellectual disability, is eminently treatable pharmacologically with psychostimulants, amongst other medications, and also psychosocial intervention which includes cognitive behavioural therapy.[44] Well-controlled observational studies and clinical trials reveal that when core symptoms are successfully treated there is a concomitant positive impact on educational performance[45] and quality of life,[46] whereas discontinuation of therapy leads to a decline in grade point average.[47] Whether treatment effects extend to the range of health outcomes associated with ADHD herein – as apparent for suicide attempt,[48] unintentional injury,[22, 49] and criminality[50] – requires further study and we did not have data on prescriptions dispensed to investigate the impact of education.

While correlations between a growing array of adverse health outcomes and antecedent ADHD are being reported, these cohort studies, like our own, are generated using electronic health records. Such studies are typically not well-equipped to examine the mechanisms underpinning these associations. For this to occur, field-based cohorts with higher resolution measurement of risk indices such as health behaviours (e.g., alcohol intake, physical activity) and biomarkers (e.g., inflammation, blood glucose) are

required. Also, the impact of ADHD treatment, which has a significant effect on outcomes, was not included.

In conclusion, children and adolescents with ADHD in the present study had an increased future burden of psychological and neurological conditions but not somatic disorders.

References

1.   Barker DJ, Osmond C. Infant mortality, childhood nutrition, and ischaemic heart disease in England and Wales. *Lancet* 1986; **1**(8489): 1077-81.
2.   Sutcliffe S, Colditz GA. Prostate cancer: is it time to expand the research focus to early-life exposures? *Nat Rev Cancer* 2013; **13**(3): 208-518.
3.   Colditz GA, Toriola AT. Refining the Focus on Early Life and Adolescent Pathways to Prevent Breast Cancer. *J Natl Cancer Inst* 2021; **113**(6): 658-9.
4.   Stefan N, Haring HU, Hu FB, Schulze MB. Divergent associations of height with cardiometabolic disease and cancer: epidemiology, pathophysiology, and global implications. *Lancet Diabetes Endocrinol* 2016; **4**(5): 457-67.
5.   Batty GD, Barzi F, Woodward M, Jamrozik K, Woo J, Kim HC, Ueshima H, Huxley RR. Adult height and cancer mortality in Asia: the Asia Pacific Cohort Studies Collaboration. *Ann Oncol* 2010; **21**(3): 646-54.
6.   Dalsgaard S, Ostergaard SD, Leckman JF, Mortensen PB, Pedersen MG. Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. *Lancet* 2015; **385**(9983): 2190-6.
7.   Catalá-López F, Hutton B, Page MJ, Driver JA, Ridao M, Alonso-Arroyo A, Valencia A, Macías Saint-Gerons D, Tabarés-Seisdedos R. Mortality in Persons With Autism Spectrum Disorder or Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis. *JAMA Pediatr* 2022; **176**(4): e216401.
8.   Truesdale M, Melville C, Barlow F, Dunn K, Henderson A, Hughes-McCormack LA, McGarty A, Rydzewska E, Smith GS, Symonds J, Jani B, Kinnear D. Respiratory-associated deaths in people with intellectual disabilities: a systematic review and meta-analysis. *BMJ Open* 2021; **11**(7): e043658.
9.   Brander G, Isomura K, Chang Z, Kuja-Halkola R, Almqvist C, Larsson H, Mataix-Cols D, Fernández de la Cruz L. Association of Tourette Syndrome and Chronic Tic Disorder With Metabolic and Cardiovascular Disorders. *JAMA Neurol* 2019; **76**(4): 454-61.
10.   Cortese S, Song M, Farhat LC, Yon DK, Lee SW, Kim MS, Park S, Oh JW, Lee S, Cheon KA, Smith L, Gosling CJ, Polanczyk GV, Larsson H, Rohde LA, et al. Incidence, prevalence, and global burden of ADHD from 1990 to 2019 across 204 countries: data, with critical re-analysis, from the Global Burden of Disease study. *Mol Psychiatry* 2023; **28**(11): 4823-30.
11.   American Psychiatric Association D, Association AP. Diagnostic and statistical manual of mental disorders: DSM-5: American psychiatric association Washington, DC; 2013.
12.   Chaulagain A, Lyhmann I, Halmøy A, Widding-Havneraas T, Nyttingnes O, Bjelland I, Mykletun A. A systematic meta-review of systematic reviews on attention deficit hyperactivity disorder. *Eur Psychiatry* 2023; **66**(1): e90.
13.   Groenman AP, Janssen TWP, Oosterlaan J. Childhood Psychiatric Disorders as Risk Factor for Subsequent Substance Abuse: A Meta-Analysis. *J Am Acad Child Adolesc Psychiatry* 2017; **56**(7): 556-69.
14.   Meinzer MC, Pettit JW, Waxmonsky JG, Gnagy E, Molina BS, Pelham WE. Does childhood attention-deficit/hyperactivity disorder (ADHD) predict levels of depressive symptoms during emerging adulthood? *Journal of abnormal child psychology* 2016; **44**: 787-97.
15.   Biederman J, Petty CR, Monuteaux MC, Fried R, Byrne D, Mirto T, Spencer T, Wilens TE, Faraone SV. Adult psychiatric outcomes of girls with attention deficit hyperactivity disorder: 11-year follow-up in a longitudinal case-control study. *American journal of psychiatry* 2010; **167**(4): 409-17.
16.   Shaw M, Hodgkins P, Caci H, Young S, Kahle J, Woods AG, Arnold LE. A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment. *BMC Med* 2012; **10**: 99.
17.   Klein RG, Mannuzza S, Olazagasti MA, Roizen E, Hutchison JA, Lashua EC, Castellanos FX. Clinical and functional outcome of childhood attention-deficit/hyperactivity disorder 33 years later. *Arch Gen Psychiatry* 2012; **69**(12): 1295-303.
18.   Garcia-Argibay M, Li L, Du Rietz E, Zhang L, Yao H, Jendle J, Ramos-Quiroga JA, Ribasés M, Chang Z, Brikell I, Cortese S, Larsson H. The association between type 2 diabetes and attention-deficit/hyperactivity disorder: A systematic review, meta-analysis, and population-based sibling study. *Neurosci Biobehav Rev* 2023; **147**: 105076.
19.   Levine SZ, Rotstein A, Kodesh A, Sandin S, Lee BK, Weinstein G, Schnaider Beeri M, Reichenberg A. Adult Attention-Deficit/Hyperactivity Disorder and the Risk of Dementia. *JAMA Netw Open* 2023; **6**(10): e2338088.

20. Li L, Yao H, Zhang L, Garcia-Argibay M, Du Rietz E, Brikell I, Solmi M, Cortese S, Ramos-Quiroga JA, Ribasés M, Chang Z, Larsson H. Attention-deficit/hyperactivity disorder is associated with increased risk of cardiovascular diseases: A systematic review and meta-analysis. *JCPP Adv* 2023; **3**(3): e12158.

21. Merzon E, Weiss MD, Cortese S, Rotem A, Schneider T, Craig SG, Vinker S, Golan Cohen A, Green I, Ashkenazi S, Weizman A, Manor I. The Association between ADHD and the Severity of COVID-19 Infection. *J Atten Disord* 2022; **26**(4): 491-501.

22. Chang Z, Lichtenstein P, D'Onofrio BM, Sjölander A, Larsson H. Serious transport accidents in adults with attention-deficit/hyperactivity disorder and the effect of medication: a population-based study. *JAMA Psychiatry* 2014; **71**(3): 319-25.

23. Pievsky MA, McGrath RE. The Neurocognitive Profile of Attention-Deficit/Hyperactivity Disorder: A Review of Meta-Analyses. *Arch Clin Neuropsychol* 2018; **33**(2): 143-57.

24. John A, Friedmann Y, DelPozo-Banos M, Frizzati A, Ford T, Thapar A. Association of school absence and exclusion with recorded neurodevelopmental disorders, mental disorders, or self-harm: a nationwide, retrospective, electronic cohort study of children and young people in Wales, UK. *Lancet Psychiatry* 2022; **9**(1): 23-34.

25. Kivimäki M, Batty GD, Pentti J, Shipley MJ, Sipilä PN, Nyberg ST, Suominen SB, Oksanen T, Stenholm S, Virtanen M, Marmot MG, Singh-Manoux A, Brunner EJ, Lindbohm JV, Ferrie JE, Vahtera J. Association between socioeconomic status and the development of mental and physical health conditions in adulthood: a multi-cohort study. *Lancet Public Health* 2020; **5**(3): e140-e9.

26. Paananen R, Gissler M. Cohort profile: the 1987 Finnish Birth Cohort. *Int J Epidemiol* 2012; **41**(4): 941-5.

27. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, Initiative S. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Lancet* 2007; **370**(9596): 1453-7.

28. Haukka J. Finnish health and social welfare registers in epidemiological research. *Norsk epidemiologi* 2004; **14**(1).

29. Dunn OJ. Multiple comparisons among means. *Journal of the American statistical association* 1961; **56**(293): 52-64.

30. Stringhini S, Zaninotto P, Kumari M, Kivimaki M, Lassale C, Batty GD. Socio-economic trajectories and cardiovascular disease mortality in older people: the English Longitudinal Study of Ageing. *Int J Epidemiol* 2018; **47**(1): 36-46.

31. Lee SS, Humphreys KL, Flory K, Liu R, Glass K. Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: a meta-analytic review. *Clin Psychol Rev* 2011; **31**(3): 328-41.

32. Sundquist J, Ohlsson H, Sundquist K, Kendler KS. Attention-deficit/hyperactivity disorder and risk for drug use disorder: a population-based follow-up and co-relative study. *Psychol Med* 2015; **45**(5): 977-83.

33. Charach A, Yeung E, Climans T, Lillie E. Childhood attention-deficit/hyperactivity disorder and future substance use disorders: comparative meta-analyses. *J Am Acad Child Adolesc Psychiatry* 2011; **50**(1): 9-21.

34. McClernon FJ, Kollins SH. ADHD and smoking: from genes to brain to behavior. *Ann N Y Acad Sci* 2008; **1141**: 131-47.

35. Bertelsen EN, Larsen JT, Petersen L, Christensen J, Dalsgaard S. Childhood Epilepsy, Febrile Seizures, and Subsequent Risk of ADHD. *Pediatrics* 2016; **138**(2).

36. Chou IC, Chang YT, Chin ZN, Muo CH, Sung FC, Kuo HT, Tsai CH, Kao CH. Correlation between epilepsy and attention deficit hyperactivity disorder: a population-based cohort study. *PLoS One* 2013; **8**(3): e57926.

37. Chou IC, Lin CC, Sung FC, Kao CH. Attention-deficit hyperactivity disorder increases the risk of deliberate self-poisoning: A population-based cohort. *Eur Psychiatry* 2014; **29**(8): 523-7.

38. Ruiz-Goikoetxea M, Cortese S, Magallón S, Aznárez-Sanado M, Álvarez Zallo N, Luis EO, de Castro-Manglano P, Soutullo C, Arrondo G. Risk of poisoning in children and adolescents with ADHD: a systematic review and meta-analysis. *Sci Rep* 2018; **8**(1): 7584.

39. Fitzgerald C, Dalsgaard S, Nordentoft M, Erlangsen A. Suicidal behaviour among persons with attention-deficit hyperactivity disorder. *Br J Psychiatry* 2019: 1-6.

40. Whitley E, Batty GD, Gale CR, Deary IJ, Tynelius P, Rasmussen F. Intelligence in early adulthood and subsequent risk of unintentional injury over two decades: cohort study of 1 109 475 Swedish men. *J Epidemiol Community Health* 2010; **64**(5): 419-25.

41.	Deary IJ, Strand S, Smith P, Fernandes C. Intelligence and educational achievement. *Intelligence* 2007; **35**: 13-21.
42.	Reme BA, Røgeberg O, Torvik FA. School performance and the social gradient in young adult death in Norway. *Nat Hum Behav* 2025; **9**(1): 84-9.
43.	Oura P, Ala-Mursula L, Chamberlain A, Junno JA, Rissanen I. Family's socioeconomic profile at birth and offspring mortality until midlife - The Northern Finland Birth Cohort 1966 study. *Prev Med* 2022; **155**: 106934.
44.	Faraone SV, Banaschewski T, Coghill D, Zheng Y, Biederman J, Bellgrove MA, Newcorn JH, Gignac M, Al Saud NM, Manor I, Rohde LA, Yang L, Cortese S, Almagor D, Stein MA, et al. The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder. *Neurosci Biobehav Rev* 2021; **128**: 789-818.
45.	Jangmo A, Stålhandske A, Chang Z, Chen Q, Almqvist C, Feldman I, Bulik CM, Lichtenstein P, D'Onofrio B, Kuja-Halkola R, Larsson H. Attention-Deficit/Hyperactivity Disorder, School Performance, and Effect of Medication. *J Am Acad Child Adolesc Psychiatry* 2019; **58**(4): 423-32.
46.	Bellato A, Perrott NJ, Marzulli L, Parlatini V, Coghill D, Cortese S. Systematic Review and Meta-Analysis: Effects of Pharmacological Treatment for Attention-Deficit/Hyperactivity Disorder on Quality of Life. *J Am Acad Child Adolesc Psychiatry* 2024.
47.	Keilow M, Holm A, Fallesen P. Medical treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and children's academic performance. *PLoS One* 2018; **13**(11): e0207905.
48.	Huang KL, Wei HT, Hsu JW, Bai YM, Su TP, Li CT, Lin WC, Tsai SJ, Chang WH, Chen TJ, Chen MH. Risk of suicide attempts in adolescents and young adults with attention-deficit hyperactivity disorder: a nationwide longitudinal study. *Br J Psychiatry* 2018; **212**(4): 234-8.
49.	Dalsgaard S, Leckman JF, Mortensen PB, Nielsen HS, Simonsen M. Effect of drugs on the risk of injuries in children with attention deficit hyperactivity disorder: a prospective cohort study. *Lancet Psychiatry* 2015; **2**(8): 702-9.
50.	Lichtenstein P, Halldner L, Zetterqvist J, Sjölander A, Serlachius E, Fazel S, Långström N, Larsson H. Medication for attention deficit-hyperactivity disorder and criminality. *N Engl J Med* 2012; **367**(21): 2006-14.

**Table 1. Study member characteristics according to ADHD diagnosis:
The 1987 Finnish Birth Cohort (N=53147)**

	ADHD	
	Yes	**No**
Population at risk, N (%)	228 (0.4)	52919 (99.6)
Male, N (%)	197 (86.4)	27219 (51.4)
Grade point average (mean, SD)	6.89 (0.77)	7.77 (0.92)
Duration of parents' social income claim (months) (mean, SD)	47.3 (73.4)	17.3 (44.6)
Any hospitalisation (in- or out-patient)	208 (91.2)	46874 (88.6)

Figure 1. Flow of study members into the analytical sample

Figure 2. Odds ratios (99.6% confidence intervals) for the association between ADHD diagnosis and subsequent hospitalisation for 14 health conditions (N=53147)

ICD chapter	Number of events (ADHD cases)	Number of events (ADHD free)	Model 1		Model 2		Percent cha
I (A01-B89) Infections	45	6372		1.96 [1.19-3.17]		1.64 [0.99-2.63]	27
IV (E0C-E35) Endocrine diseases	14	2064		2.27 [0.90-4.72]		2.00 [0.80-4.18]	15
V (F00-F99) Mental and behavioural disorders	109	9772		4.66 [3.29-7.20]		3.51 [2.35-5.22]	20
VI (G00-G99) Diseases of the nervous system	44	6763		2.35 [1.40 3.76]		1.81 [1.07 2.91]	30
VII (H00-H59) Diseases of the eye	40	6017		2.22 [1.29-3.60]		2.04 [1.19-3.33]	12
VIII (H60-H99) Diseases of the ear	16	2589		1.79 [0.76-3.56]		1.48 [0.63-2.95]	32
IX (I00-I99) Diseases of the circulatory system	22	4013		1.38 [0.67-2.53]		1.21 [0.59-2.22]	41
X (J00-J99) Diseases of the respiratory system	61	11092		1.55 [0.95-2.37]		1.31 [0.83-2.01]	38
XI (K00-K93) Diseases of the digestive system	51	10176		1.33 [0.82-2.08]		1.11 [0.88-1.74]	63
XII (L00-L99) Diseases of the skin	33	6440		1.63 [0.94-2.67]		1.29 [0.74-2.12]	47
XIII (M00-M99) Diseases of the musculoskeletal system	70	11809		1.65 [1.07-2.49]		1.28 [0.84-1.94]	50
XIV (N00-N99) Diseases of the genitourinary system	34	10770		1.40 [0.77-2.41]		1.18 [0.64-2.03]	61
XIX (S00-T65) Injury and poisoning	130	19271		1.85 [1.25-2.76]		1.42 [0.95-2.13]	42
XXI (V01-X84) External causes	107	15927		1.71 [1.16-2.53]		1.36 [0.91-2.01]	43

Odds ratios are the odds of a given outcome in people with an ADHD diagnosis versus the those without (the referent).
Model 1 comprises sex, and Model 2 sex, family socioeconomic status, and study members' educational performance.
As a birth cohort, there is no variation in age in the study sample, so no such adjustment was required.
All effect estimates are corrected for multiple testing.

Figure 3. Odds ratios (99.7% confidence intervals) for the association between ADHD diagnosis and subsequent hospitalisation for 17 health conditions (N=53147)

ICD grouping	Number of events (ADHD cases)	Number of events (ADHD free)	Model 1	Model 2	Percent chan
A01-A79 Bacterial infections	33	4822	1.90 [1.04-3.22]	1.60 [0.87-2.72]	28.
A80-B34 Viral infections	16	1652	2.42 [1.01-4.86]	1.64 [0.76-3.73]	31.
F10-F19 Disorders due to substance abuse	40	2286	4.10 [2.36-6.75]	2.27 [1.28-3.81]	42.
F20-F29 Psychotic disorders	15	1166	2.93 [1.19-6.04]	2.11 [0.85-4.38]	30.
F30-F39 Mood disorders	54	5596	3.39 [2.07-5.32]	2.46 [1.50-3.90]	26.
F40-F48 Neurotic disorders	47	5436	2.98 [1.77-4.76]	2.12 [1.25-3.43]	31.
G40-G42 Epilepsy	15	814	6.36 [2.56-13.23]	4.65 [1.86-8.75]	17.
G43-G44 Headaches	11	2549	1.63 [0.56-3.73]	1.25 [0.42-2.86]	55.
J09-J18 Influenza and Pneumonia	11	1740	1.56 [0.53-3.53]	1.23 [0.42-2.79]	54.
L00-L08, L20-L30 Infections and eczema	24	4220	1.60 [0.78-2.89]	1.21 [0.60-2.21]	58.
M50-M51 Sciatica	13	1310	2.42 [0.91-5.20]	1.83 [0.69-3.96]	31
M54 Back pain	21	3687	1.55 [0.73-2.92]	1.06 [0.49-2.00]	67.
M60-M79 Soft tissue disorders	33	4215	2.20 [1.20-3.74]	1.71 [0.93-2.92]	32.
S00-T35 Injury	128	19814	1.64 [1.23-2.76]	1.43 [0.96-2.15]	41.
T36-T65 Poisoning	19	1262	3.95 [1.78-7.65]	2.30 [1.02-4.61]	39.
V01-V99 Road accidents	25	2654	2.04 [1.02-3.68]	1.56 [0.78-2.83]	37
W00-W19 Falls	46	6749	1.64 [0.98-2.61]	1.34 [0.80-2.13]	41.

Odds ratios are the odds of a given outcome in people with an ADHD diagnosis versus the those without (the referent).
Model 1 comprises sex, and Model 2 sex, family socioeconomic status, and study members' educational performance.
As a birth cohort, there is no variation in age in the study sample so no such adjustment was required.
All effect estimates are corrected for multiple testing.

Supplemental Table 1. Study member characteristics in relation to total mortality in the 1987 Finnish Birth Cohort Study (N=59476)

	Total mortality	
	N events / N at risk	**OR (95% CI)**
Male	459 / 30435	2.95 [2.46-3.56]
Female	150 / 29041	1.0 (ref)
Low grade point average	294 / 14821	2.37 [2.01-2.79]
High grade point average	315 / 44655	1.0 (ref)
Months claiming social income (per SD higher)	609 / 59476	1.28 [1.21-1.34]
ADHD diagnosis	8 / 279	2.15 [0.97-4.08]
ADHD free	601 / 59197	1.0 (ref)

ORs are sex-adjusted except in the analyses of risk according to sex where they are unadjusted. For GPA, ORs are for low (4-7) versus high [7-10]. Follow-up was to 2020. A SD increase in duration claiming social income is 45.74 months.